CytRX has a revolutionary cancer breakthrough with the potential to help save millions. Aldoxorubicin can be continually administered without Cardio Toxicity and minimal to no hair loss. Corporate greed is fueling the delay in bringing these products to our families, friends and loved ones. We have all been affected by cancer in some way, we now have a chance to do something about it....

Start date: 07/16/2007
End date: 07/13/2017
Start price/share: $22.56
End price/share: $0.63
Starting shares: 443.26M
Ending shares: 514.47M
Dividends reinvested/share: $1.74
Total return: -96.76%
Average Annual Total Return: -29.03%

Steven A. Kriegsman should resign effective immediately based on gross lack of shareholder interest over the last 10 years and refusing to bring to market life changing chemotherapeutic treatments that could potentially save the lives of cancer patients across the world.